Dengue Vaccine
Dengue fever · Dengue hemorrhagic fever · Dengue shock syndrome
Dengue is the most rapidly spreading mosquito-borne viral disease globally — infecting 390 million people annually with 100 million symptomatic cases. Four serotypes exist (DENV 1–4). Secondary infection with a different serotype dramatically increases risk of severe dengue hemorrhagic fever through antibody-dependent enhancement (ADE). The dengue vaccine controversy — specifically the Dengvaxia disaster in the Philippines — is one of the most significant vaccine safety events of recent decades.
Overall Benefit Score
Default scenario · 12-month-old · US community (92% vax rate)
Score for your child →The risk-benefit balance in your specific scenario suggests a detailed conversation with your child's provider before deciding.
📊 Evidence Scores
Scores computed from peer-reviewed data using VaxFact's evidence model. Based on default scenario (12-month-old, standard US community).
🦠 Disease Burden
Dengue is the most rapidly spreading mosquito-borne viral disease globally — infecting 390 million people annually with 100 million symptomatic cases. Four serotypes exist (DENV 1–4). Secondary infection with a different serotype dramatically increases risk of severe dengue hemorrhagic fever through antibody-dependent enhancement (ADE). The dengue vaccine controversy — specifically the Dengvaxia disaster in the Philippines — is one of the most significant vaccine safety events of recent decades.
Mild dengue: severe flu-like illness with intense joint pain ('breakbone fever') for 5–7 days. Severe dengue: plasma leakage, hemorrhage, organ impairment. Case fatality of severe dengue: 1–5% without treatment. 20,000+ dengue deaths annually.
🛡️ Vaccine Effectiveness
Dengvaxia: 60% effective overall in seropositive individuals; acts as a 'prime' for seronegative individuals — increasing severe dengue risk on subsequent infection due to ADE mechanism. Qdenga (TAK-003) does not have this seronegative concern and shows ~80% efficacy against DENV 2, lower against DENV 1/3/4.
Dengvaxia is contraindicated in seronegative individuals — this is the fundamental lesson from the Philippines disaster (see credible critiques).
⚠️ Adverse Events & Side Effects
All probabilities are per 100,000 doses administered, sourced from VAERS, Vaccine Safety Datalink, and post-licensure surveillance studies.
Common Side Effects
Rare Serious Events
📅 Vaccine Schedule
Dengvaxia: ONLY administer to confirmed seropositive individuals (prior dengue infection confirmed by serology). Qdenga: no seropositivity requirement — preferred option where available. For travelers: currently limited recommendations; Qdenga being evaluated for traveler use.
⚖️ Benefits vs. Considerations
✓ Benefits
- Qdenga (newer vaccine) does not have the seronegative safety concern
- Provides meaningful protection against the leading mosquito-borne viral disease globally
- Prevents severe dengue hemorrhagic fever in seropositive individuals
- Important tool in endemic regions where repeat infections are common
↕ Considerations
- Dengvaxia caused deaths in Philippine children — one of the most significant vaccine disasters in recent history
- Dengvaxia contraindicated in seronegative individuals — fundamental limitation requiring serology testing
- Moderate effectiveness (50–62%) even in seropositive individuals
- Not recommended for most US travelers to endemic areas (limited access, serostatus unknown)
- Complex 3-dose schedule over 12 months
🔬 What Some Researchers Question
These are legitimate scientific debates — not fringe claims. They represent areas of ongoing research or policy disagreement among credentialed experts.
- The Dengvaxia Philippines disaster is one of the most important vaccine safety events of the 21st century and must be understood by anyone discussing dengue vaccination. The Philippine DOH launched a school-based mass vaccination program (800,000 children) in 2016 without mandatory pre-screening for dengue serostatus. When Sanofi disclosed that seronegative vaccinees faced increased risk of severe dengue, the program was suspended. Hospitalizations and deaths followed. The event severely damaged vaccine confidence in the Philippines and across Southeast Asia, and resulted in criminal charges against health officials. It is a documented case where a vaccine caused net harm to a specific population (seronegative children) due to inadequate pre-vaccination screening (Aguiar et al., 2019).
🌫️ Scientific Uncertainties
Honest acknowledgment of what we don't yet know with confidence.
- Long-term effectiveness of Qdenga beyond 4.5 years of follow-up
- Effectiveness of Qdenga against all four dengue serotypes — particularly DENV 3 and 4
- Whether Qdenga will receive recommendations for international travelers — currently not standardly recommended for travel
🌍 International Policy Comparison
How different countries approach this vaccine — revealing where global consensus is strong vs. where policy diverges.